Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;14(Suppl 1):74-81.
doi: 10.1007/s13193-022-01640-5. Epub 2022 Sep 7.

Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer - a Retrospective Study by INDEPSO

Snita Sinukumar  1   2 , Dileep Damodaran  2 , Mukurdipi Ray  3 , Aruna Prabhu  4 , Ninad Katdare  5 , Syam Vikram  2 , Sakina Shaikh  6 , Ankita Patel  6 , Aditi Bhatt  6
Affiliations

Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer - a Retrospective Study by INDEPSO

Snita Sinukumar et al. Indian J Surg Oncol. 2023 Jun.

Abstract

The aim of this study was to evaluate the potential role of optimal cytoreductive surgery with or without HIPEC in the management of peritoneal dissemination from rare histological subtypes of ovarian cancer and to report the prognostic factors affecting survival. In this retrospective multicentric study, all patients with diagnosis of locally advanced ca ovary with histology other than high-grade serous carcinoma and those having undergone cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy for the same were included. Factors affecting survival were evaluated in addition to studying the clinicopathological features. In the period from January 2013 to December 2021, 101 consecutive patients of ovarian cancer with rare histology underwent cytoreductive surgery with or without HIPEC. The median OS was not reached (NR), and the median PFS was 60 months. On evaluation of factors affecting overall survival (OS) and progression-free survival (PFS), PCI > 15 was associated with not only a decreased PFS (p = 0.019) but also a decreased OS (P = 0.019) on univariate and multivariate analysis. With respect to histology, the best OS and PFS were seen with granulosa cell tumor, mucinous tumors for which median OS and median PFS were NR respectively. Cytoreductive surgery can be performed with an acceptable morbidity in patients with peritoneal dissemination from ovarian tumors of rare histology. The role of HIPEC and impact of other prognostic factors on the treatment and survival outcome need further evaluation in larger series of patients.

Supplementary information: The online version contains supplementary material available at 10.1007/s13193-022-01640-5.

Keywords: Cytoreductive surgery; HIPEC; Rare ovarian histology.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
a, b: Kaplan–Meir curve: overall survival and progression-free survival, separated by histology
Fig. 2
Fig. 2
a, b, c, d Impact of HIPEC on Overall Survival and Progression free survival of rare ovarian histology
See this image and copyright information in PMC

References

    1. McCluggage W. Glenn (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43(5) :4220–432 - PubMed
    1. Kurman, RJ. ShihIe-Ming (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186(4):733–747 - PMC - PubMed
    1. Shimada M, Kigawa J, Ohishi Y et al. (2009) Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113(3):331–334 - PubMed
    1. Morice P, Gouy S, Leary A, et al. N Engl J Med. 2019;380(13):1256–1266. doi: 10.1056/NEJMra1813254. - DOI - PubMed
    1. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–40 - PubMed

LinkOut - more resources